2 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
Follow AMG 330: new trials by email Literature Review of AMG 330 trials Research Report on AMG 330
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia AMG 330, Pembrolizumab - Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Terminated | Amgen | 1 | 2020-09-29 | 2024-03-08 |
| A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies AMG 330 - Relapsed/Refractory AML, Minimal Residual Disease Positive AML | Phase 1 | Terminated | Amgen | 95 | 2015-08-31 | 2024-07-31 |
Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Recurrence (1)
Amgen (2)
United States (2) · Canada (1) · Germany (1) · Netherlands (1)
2014 (1)